IQVIA (NYSE:IQV) Hits New 1-Year High - Here's Why

Key Points

• IQVIA shares reached a new 52-week high of $266.08, supported by analyst upgrades from JPMorgan and TD Cowen. The stock has a “Moderate Buy” consensus rating, with a consensus price target of $241.88.
• The company beat quarterly expectations, reporting $3.15 in adjusted EPS and $4.37 billion in revenue; revenue rose 8.7% year over year. IQVIA issued fiscal 2026 EPS guidance of $12.80–$13.00.
• IQVIA authorized a $2 billion share-repurchase program, equivalent to up to 6.8% of outstanding shares, while insiders sold about $3.1 million of stock over the past 90 days.

IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) shares hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $266.08 and last traded at $265.7970, with a volume of 567514 shares changing hands. The stock had previously closed at $258.35.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of analyst reports. JPMorgan Chase & Co. lifted their target price on shares of IQVIA from $225.00 to $285.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 29th. TD Cowen raised their price target on shares of IQVIA from $233.00 to $288.00 and gave the stock a "buy" rating in a report on Wednesday, July 29th. Mizuho upped their price objective on shares of IQVIA from $215.00 to $230.00 and gave the company an "outperform" rating in a research note on Monday, July 13th. Weiss Ratings upgraded shares of IQVIA from a "hold (c-)" rating to a "hold (c)" rating in a report on Wednesday, July 15th. Finally, Wall Street Zen downgraded IQVIA from a "buy" rating to a "hold" rating in a report on Saturday. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, IQVIA has a consensus rating of "Moderate Buy" and a consensus target price of $241.88.

IQVIA Price Performance

The firm's 50 day moving average is $225.75 and its 200 day moving average is $190.73. The firm has a market cap of $43.56 billion, a P/E ratio of 32.91, a price-to-earnings-growth ratio of 2.23 and a beta of 1.18. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating analysts' consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm had revenue of $4.37 billion for the quarter, compared to analysts' expectations of $4.30 billion. During the same quarter in the prior year, the company posted $2.81 earnings per share. The business's revenue for the quarter was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA declared that its Board of Directors has approved a share buyback program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company's board believes its shares are undervalued.

Insider Buying and Selling

In other news, insider Bhavik Patel sold 1,855 shares of the business's stock in a transaction on Friday, July 31st. The shares were sold at an average price of $235.27, for a total value of $436,425.85. Following the transaction, the insider owned 1,348 shares of the company's stock, valued at approximately $317,143.96. The trade was a 57.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Keriann Cherofsky sold 558 shares of the company's stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the transaction, the insider owned 2,989 shares of the company's stock, valued at approximately $732,932.69. This represents a 15.73% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 12,913 shares of company stock worth $3,098,793 over the last ninety days. 1.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. International Assets Investment Management LLC purchased a new position in shares of IQVIA in the 4th quarter valued at $27,000. Compass Financial Management LLC bought a new stake in IQVIA during the second quarter valued at about $27,000. Gilpin Wealth Management LLC purchased a new position in IQVIA in the fourth quarter valued at about $27,000. CrossGen Wealth LLC bought a new position in IQVIA in the fourth quarter worth about $28,000. Finally, Financial Freedom LLC purchased a new stake in shares of IQVIA during the first quarter valued at about $25,000. Institutional investors own 89.62% of the company's stock.

About IQVIA

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source